Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pembrolizumab, a humanized IgG4 monoclonal antibody targeting programmed death-1 protein, has demonstrated efficacy in relapsed/refractory classical Hodgkin lymphoma (cHL). To assess the complete metabolic response (CMR) rate and safety of pembrolizumab monotherapy in newly diagnosed cHL, we conduct...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Allen, Pamela B., Savas, Hatice, Evens, Andrew M., Advani, Ranjana H., Palmer, Brett, Pro, Barbara, Karmali, Reem, Mou, Eric, Bearden, Jeffrey, Dillehay, Gary, Bayer, Robert A., Eisner, Robert M., Chmiel, Joan S., O’Shea, Kaitlyn, Gordon, Leo I., Winter, Jane N.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2021
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955404/
https://ncbi.nlm.nih.gov/pubmed/32992341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007400
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker